Unipr

Unipr AI Agents streamline project-centric workflows by automating repetitive tasks such as planning, resource allocation, coordination, budgeting, and risk analysis. https://lnkd.in/eSPcsTBy

Consider this: A 200 million deficit in Q4 R&D budget, coupled with significant FTE gaps across functions. This scenario, all too common, stems from our reliance on disconnected workflows and data silos. The solution isn't about forcing everyone onto a single platform. Instead, we need to: 🔗 Unite data, tools, and workflows to accelerate execution 🛠️ Fill capability gaps without disrupting existing tools 📈 Leverage AI for predictive KPIs and leading indicators As Rohan Murty and Sandeep Dadlani note in their HBR article, "In an ideal world, all systems in an organization would be integrated with each other in the backend with APIs and seamlessly talk to each other." At Unipr, we're making this ideal world a reality. By unifying disparate data and generating real-time predictive insights, we're transforming how biopharma companies manage their portfolios and operations. The path to faster, more efficient drug development and commercialization is clear. It's time we embrace the power of connected systems and AI-driven insights. Are you ready to unlock the full potential of your R&D pipeline? Let's connect and explore how Unipr can revolutionize your approach to life sciences innovation. #LifeSciencesInnovation #AIinPharma #DataUnification #UniprTransformation https://lnkd.in/gkvZpXGM

In 2023, the global biopharma industry generated $1.6 trillion, with 152 blockbuster drugs contributing $511 billion—a third of the total. Launching blockbusters isn’t optional for the top companies—it’s essential to sustain growth and meet Wall Street expectations. Today, most top biopharma companies get a significant part of their revenues from (blockbusters): AbbVie (11) and Gilead Sciences (7) 83%, Novo Nordisk (9) 80%, Bristol Myers Squibb (8) and AstraZeneca (12) 74%, Novartis (13) and Eli Lilly and Company (6) 72%, Merck (6) 70%, Pfizer (10) 68%, Roche (15) and GSK (10) 59%, Johnson & Johnson (13) 52%, Amgen (9) 49%, Takeda (4) 33%, Sanofi (6) 31%, and Bayer (3) 14%. Yet, leading companies continually leave money on the table every year. Why is that? Complex global launches demand seamless, real-time, cross-functional collaboration. However, siloed workflows, disconnected tools, and fragmented processes continue to disrupt execution. Most teams rely on retrospective metrics, focusing on past actions with little foresight into emerging risks. Also, using static frameworks affects agility. Teams can’t adapt rapidly to dynamic regulatory, competitive, or operational shifts. The launch paradigm for companies launching in 2025 and beyond ought to be: "Same Day Launch" i.e. products available to patients within 24 hours of regulatory approval in every market. No longer a pipe dream, such ambitious goals can be well within reach by refining operations along three pillars: 1. Organizational Alignment: United tools and systems must persistently connect internal and external teams in real-time, eliminating data silos and fostering coordination. Unipr AI Ecosystem does precisely that. 2. Execution Foresight: Predictive AI helps leaders foresee delays, anticipate risks, and mitigate issues before they escalate. Unipr AI is built to predict operational bottlenecks and recommend actionable solutions. 3. Operational Agility: Static plans falter in dynamic environments; tactical agility is essential to pivot effectively when strategies change in response to changes in the launch environment. Unipr AI Platform equips teams to prepare for multiple scenarios and ensures rapid adaptation. Modern launch success isn’t about short-term intense preparation when approval nears. Excellence means enduring cross-functional alignment. So that operating seamlessly is not an exception, its just business as usual. With patent cliffs looming over many top biopharma companies and the exclusivity clock ticking for upcoming launches, operational precision offers extraordinary rewards: faster market entry and competitive advantage. Companies no longer need to leave millions on the table. With foresight, alignment, and agility, executives can ensure upcoming blockbusters reach their full potential—and more patients—without delay. A deeper dive into why current approaches fall short and a new way forward in the article below:

Insights from Alison Conlon, former Head of Corporate Operations at Sail Biomedicines: The world of biotech program management isn’t just about timelines—it’s about creating a seamless flow of information across teams and functions, from early research through product development. In biotech, success is measured in years, not weeks, and that means our tools must evolve to support long-term, high-stakes decision-making. Too often, the tools we rely on for planning aren’t built to communicate, which means valuable time is lost gathering updates rather than making quality decisions. Alison notes that adopting advanced technology early on streamlines program operations and scales seamlessly as the portfolio grows. 'If we want different results than what we had in the past, we must do things differently,' she emphasizes. It’s time for tools that eliminate data silos, boost transparency, and automate administrative tasks, so program leaders can focus on strategy and outcomes. As program management evolves, so too must our tech. Here’s to building agile, efficient, and connected biotech organizations. Watch the full interview: https://lnkd.in/gQsacfg6

For companies eager to bring AI into operations: start by aligning workflows and unifying your data. In life sciences, we’ve heard the same challenge from over 20 leaders—using too many disconnected tools slows down teams, creating ‘data silos’ that prevent a clear, complete view. On average, companies juggle 5+ project management tools. This setup makes collaboration tough and swapping out tools even tougher. A unified workspace where all teams can share relevant workflows, like the Apple Health app but for projects, has felt like a dream...until now. One biopharma COO shared how Unipr solved this for their teams: ‘Unipr removed hard interfaces between projects; now we move faster without needing constant handoffs. Those friction points are gone.’ Unipr connects projects across tools, letting teams from R&D, Commercial, Manufacturing, and beyond work in sync—without giving up their go-to platforms. If your teams are stuck in disconnected systems, see how Unipr can bring them together for better collaboration and speed. Visit www.unipr.com to learn more.

Unleashing the CEO Within: From Biopharma PM to Industry Leader 🚀 Ever wondered if your role as a PM in biopharma could lead to the C-suite? Our CEO, Andy Mehrotra, shared his thoughts on this transformative journey: 1. PMs possess CEO-like skills: managing without authority, coordinating diverse teams, and laser focus on timelines and deliverables. 2. Yet, PMs often get stuck in tactical tasks, limiting their strategic growth. 3. AI tools can be game-changers, freeing up time for strategic thinking and problem-solving. 4. The key? Making time to think beyond the day-to-day grind. It's time for the biopharma industry to recognize and nurture the leadership potential of its PMs. Who knows? The next visionary CEO might be managing projects right now! #BiopharmaLeadership #ProductManagement #CareerGrowth #AI #Innovation

Why does planning R&D projects in life sciences take so long? Here are two major reasons: 🔄 Asynchronous Planning: Timelines, budgets, and resources are often developed separately by different teams, leading to misalignments. 🕒 Serial Knowledge Collection: Insights from subject matter experts are gathered sequentially, causing delays. Additionally, the lack of high-quality, updated templates means teams often start from scratch, further prolonging the process. If we know our goals, simultaneous planning for timelines, budgets, and resources should take minutes, not weeks. It’s time to leverage AI-enabled solutions to streamline our planning processes and turn inefficiencies into strategic advantages. What steps is your organization taking to improve R&D planning? Let’s discuss!

Insight is power—but only if it’s actionable. One ambitious biotech transformed decision-making with Unipr: real-time dashboards, drill-down searches, and predictive insights to stay ahead of every milestone. If data overwhelm is holding you back, maybe it’s time to simplify. With Unipr, every decision becomes faster and smarter. https://lnkd.in/guhFjuCn

In the coming years, Bristol Myers Squibb, Merck, Amgen, Novartis, and AstraZeneca will experience the highest level of exposure to generic and biosimilar competition, while Vertex, Gilead Sciences, Sanofi, Novo Nordisk, and Eli Lilly will be the least exposed over the 2025-2030 timeframe. From 2030 onward, however, Lilly, Gilead, and Novo are much more likely to take a hit from LOEs alongside companies like Regeneron and Biogen. Vertex, GSK, Pfizer, Takeda, and Amgen are likely to fare the best in terms of LOE exposure from 2030 through 2040. Naturally, companies are eagerly looking to acquire external high rNPV products with the potential to launch in the near term in addition to bolstering their internal R&D pipelines. The hunt for the next generation of blockbusters is on; JPM2025 promises to be fun! Yet, not every blockbuster hopeful will make it to the finish line. It would be okay if the only reason science-based products did not reach their expected potential was because of the biological variables. Today, with the ability to anticipate challenges, plan for alternative scenarios in approvals, reimbursements, and launches, and make predictive decisions to navigate future obstacles, operational variables should no longer limit the potential of years of R&D. Patients should not miss out on timely access to medicines due to preventable delays. Takeaway: The life of a drug is short; make every day count! More here: https://lnkd.in/gzJ4S5bT Reference: https://lnkd.in/gcXghPgz

Imagine if every data point needed to shape a portfolio was available, contextually connected, and updated in real-time—helping you see not only what’s happening today but anticipate what’s around the corner. The power of AI isn’t just in speeding up processes; it’s in orchestrating them with precision, from project timelines to budgets. What if when a milestone shifts, all timelines, resources, and budgets across your entire portfolio adjusted in sync? AI and predictive insights can make this a reality, creating a world where flawless execution is not just a goal, but the norm. Keeping up has never been easier for those willing to embrace change. https://lnkd.in/gnNMeEcW